Reset filter
Palabras clave
Helsesjekk ×
Mostrar más Palabras clave
Tabla de contenido
  1. 1. Ensayo clínico
  2. 2. Documentación de rutina
  3. 3. Estudio de registro / cohorte
  4. 4. Seguro de calidad
  5. 5. Estándar de datos
  6. 6. Resultado reportado por el paciente
  7. 7. Especialidad médica
Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

789 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

Visit 1 Month 0 Physical Examination Pregnancy Test Scale ECG Neurological Assessment Modified Rankin Scale PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes NCT00153062

- 20/2/17 - 1 formulario, 5 itemgroups, 32 items, 1 idioma
Itemgroups: Physical Examination, Pregnancy Test, ECG, Neurological Assessment - NIH Stroke Scale, Modified Rankin Scale
The purpose of the trial is to determine if extended-release dipyridamole + aspirin [Aggrenox, Asasa ntin] is superior to clopidogrel [Plavix], and if telmisartan [Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and therefore are at high risk of suffering another one. Visit 1 (Month 0) Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00153062?term=NCT00153062&rank=1

University Hospital Essen Documentation blood pressure, pulse, temperature

- 14/2/17 - 1 formulario, 1 itemgroup, 14 items, 1 idioma
Itemgroup: Default Itemgroup
Hospital routine documentation models at the University Hospital Essen. Tables were derived from the Medico Information System. Original table name: n2340bpt

Unscheduled Visit Physical Examination [PE_1] NCT01117584

- 4/2/17 - 1 formulario, 1 itemgroup, 3 items, 1 idioma
Itemgroup: General Information
NCT01117584 Astellas Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone.

Visit 7 / Early Termination Physical Examination [PE_1] NCT01117584 - Visit 7 / Early Termination Physical Examination [PE_1] NCT01117584

- 4/2/17 - 1 formulario, 1 itemgroup, 3 items, 1 idioma
Itemgroup: General Information
NCT01117584 Astellas Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone.

Physical examination CRFs Multiple Sclerosis Tysabri NCT00027300

- 31/1/17 - 1 formulario, 1 itemgroup, 23 items, 1 idioma
Itemgroup: Physical examination
The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS. Documentation process: This form is to be obtained in Screening, week 52, week 104, week 120, week 128 and in Premature Study Withdrawl.

Visit 2 Baseline Physical Examination [PE_1] NCT01117584

- 28/1/17 - 1 formulario, 1 itemgroup, 3 items, 1 idioma
Itemgroup: General Information
NCT01117584 Astellas Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone.

Visit 1 Run-ln Physical Examination NCT01117584

- 28/1/17 - 1 formulario, 1 itemgroup, 3 items, 1 idioma
Itemgroup: General Information
NCT01117584 Astellas Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone.

M.Alzheimer GSK - Book 4 NCT00334568/ GSK-AVA100193 - M.Alzheimer GSK - Book 4NCT00334568/ GSK-AVA100193

- 14/12/16 - 1 formulario, 10 itemgroups, 24 items, 1 idioma
Itemgroups: General information, Vital signs, Central Laboratory, Concomitant Medications, Adverse Events, Physical Examination, Pedal Oedema, Monitor Data Validation Checks, Investigational Product, End of visit reminder
NCT00334568/ GSK-AVA100193: M.Alzheimer GSK A 24 week double-blind, randomized, placebo-controlled, parallel-group dose-raging study to investigate the effects of rosiglitazone (extended release tablets) on cognition in subjects with mild to moderate Alzheimer´s disease. Medicine: rosiglitazone, Condition: Alzheimer´s Disease, Phase: 2, Clinical Study ID: AVA 100193, Sponsor: GSK. This ODM contains Book 4/Visit 4.

M.Alzheimer GSK - Book 3 NCT00334568/ GSK-AVA100193

- 14/12/16 - 1 formulario, 7 itemgroups, 15 items, 1 idioma
Itemgroups: General information, Vital Signs, Concomitant Medications, Adverse Events, Physical Examination, Pedal Oedema, End of visit reminder
NCT00334568/ GSK-AVA100193: M.Alzheimer GSK A 24 week double-blind, randomized, placebo-controlled, parallel-group dose-raging study to investigate the effects of rosiglitazone (extended release tablets) on cognition in subjects with mild to moderate Alzheimer´s disease. Medicine: rosiglitazone, Condition: Alzheimer´s Disease, Phase: 2, Clinical Study ID: AVA 100193, Sponsor: GSK. This ODM contains Book 3/Visit 3.

MS MEDB EDE-Vorstellung University Hospital Muenster (UKM)

- 7/12/16 - 1 formulario, 4 itemgroups, 19 items, 1 idioma
Itemgroups: General information, EDE presentation, Parameters, Laboratory parameters
Hospital Routine Documentation Form at the University Hospital Muenster. Original Form name: MS MEDB EDE-Vorstellung.

M.Alzheimer GSK - Book 8 NCT00334568/ GSK-AVA100193 - NCT00334568/ GSK-AVA100193: M.Alzheimer GSK - Book 8

- 5/12/16 - 1 formulario, 17 itemgroups, 34 items, 1 idioma
Itemgroups: General Information, Instructions, Vital signs, Neurological Examination, Central Laboratory (Fasting samples), Pregnancy Test, Pharmacogenetics, Pharmacological studies, Pharmacological studies, 12-Lead ECG, Concomitant Medications, Adverse Events, Physical Examination, Pedal Oedema, Rating Scale Instructions, Investigational Product Compliance, End of visit reminder
NCT00334568/ GSK-AVA100193: M.Alzheimer GSK A 24 week double-blind, randomized, placebo-controlled, parallel-group dose-raging study to investigate the effects of rosiglitazone (extended release tablets) on cognition in subjects with mild to moderate Alzheimer´s disease. Medicine: rosiglitazone, Condition: Alzheimer´s Disease, Phase: 2, Clinical Study ID: AVA 100193, Sponsor: GSK. This ODM contains Book 8/Visit 8.

M.Alzheimer GSK - Book 7 NCT00334568/ GSK-AVA100193 - NCT00334568/ GSK-AVA100193: M.Alzheimer GSK - Book 7

- 5/12/16 - 1 formulario, 10 itemgroups, 24 items, 1 idioma
Itemgroups: General Information, Vital Signs, Central Laboratory (Non fasting samples), Concomitant Medications, Adverse Events, Physical Examination, Pedal Oedema, Monitor Data Validation Checks, Investigational Product, End of Visit Reminder
NCT00334568/ GSK-AVA100193: M.Alzheimer GSK A 24 week double-blind, randomized, placebo-controlled, parallel-group dose-raging study to investigate the effects of rosiglitazone (extended release tablets) on cognition in subjects with mild to moderate Alzheimer´s disease. Medicine: rosiglitazone, Condition: Alzheimer´s Disease, Phase: 2, Clinical Study ID: AVA 100193, Sponsor: GSK. This ODM contains Book 7/Visit 7.

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial